Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

A new clinical trial has shown for the first time that taking high doses of vitamin D could stave off the progression of ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...

Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...

Feb. 27, 2025 — A new study suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI). By studying the effects of the ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis The trial ...

Learn about multiple sclerosis (MS), a condition affecting younger individuals, its symptoms, causes, diagnosis, treatment, ...